In the published article, there was an error in the affiliation. Instead of “Department of Cardiology, Drum Tower Hospital, Nanjing University Medical School, Nanjing, China”, it should be “Department of Cardiology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China”.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Summary
Keywords
empagliflozin, heart failure with preserved ejection fraction, cost-effectiveness analysis, China, pharmaco economic
Citation
Jiang Y and Xie J (2023) Corrigendum: Cost-effectiveness of adding empagliflozin to the standard therapy for Heart Failure with Preserved Ejection Fraction from the perspective of healthcare systems in China. Front. Cardiovasc. Med. 10:1205721. doi: 10.3389/fcvm.2023.1205721
Received
14 April 2023
Accepted
24 April 2023
Published
09 May 2023
Approved by
Frontiers in Cardiovascular Medicine, Frontiers Media SA, Switzerland
Volume
10 - 2023
Updates
Copyright
© 2023 Jiang and Xie.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jun Xie xiejun20192022@163.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.